
NYSE:BSX
This summary was created by AI, based on 10 opinions in the last 12 months.
Boston Scientific Corp (BSX-N) has experienced significant challenges over the past year, with major concerns regarding its organic growth and market position. Experts pointed out that the company has seen a breakdown in its uptrend and is now dealing with lower highs and lows, which has negatively impacted its stock price. Many analysts note that while the company is a leader in the medical device sector, it faces tough competition from peers such as Medtronic, Abbott, and Johnson & Johnson. The recent adjustments in growth projection have raised red flags regarding its valuation, with some analysts advising caution. Despite its strong fundamentals and long-term growth potential in the aging demographics market, the near-term technical outlook remains weak, and the consensus leans towards a watchful approach.
An extraordinarily well-run company. Great organic growth. A leader in the cardiac rhythm management, and have done that principally organically. The new management in 2012 streamlined operations, became very efficient and enhanced margins on the back of that. This is a company that he wants to continue to own.
(A Top Pick Sep 18/18, Up 11%) They make heart pacers and have expanded into joint replacements through acquisitions. It was poorly managed, but has turned around in the past three years. He's trimmed around $42 to be Pfizer. However, all medical stocks face US politicians bashing them during elections. So, load up on health stocks and do well after the vote.